SPINOCEREBELLAR ATAXIA GENOTYPE TYPE 7

Clinical trials for SPINOCEREBELLAR ATAXIA GENOTYPE TYPE 7 explained in plain language.

Never miss a new study

Get alerted when new SPINOCEREBELLAR ATAXIA GENOTYPE TYPE 7 trials appear

Sign up with your email to follow new studies for SPINOCEREBELLAR ATAXIA GENOTYPE TYPE 7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New drug trial aims to slow debilitating genetic movement disorder

Disease control Completed

This study tested whether a drug called troriluzole could help control the symptoms of spinocerebellar ataxia (SCA), a group of rare, inherited disorders that cause worsening problems with coordination and balance. For 8 weeks, 141 adults with SCA received either the drug or a pl…

Matched conditions: SPINOCEREBELLAR ATAXIA GENOTYPE TYPE 7

Phase: PHASE2, PHASE3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control

Last updated Mar 13, 2026 15:06 UTC

SPINOCEREBELLAR ATAXIA GENOTYPE TYPE 7

Get alerted when new SPINOCEREBELLAR ATAXIA GENOTYPE TYPE 7 trials appear

New drug trial aims to slow debilitating genetic movement disorder